Zhang L, Gao AX, He YL, Xu MJ, Lu HJ. Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports. World J Clin Cases 2023; 11(32): 7911-7919 [PMID: 38073679 DOI: 10.12998/wjcc.v11.i32.7911]
Corresponding Author of This Article
Hai-Jun Lu, PhD, Professor, Radiation Oncology, The Affiliated Hospital of Qingdao University, Haier Road, Qingdao 266000, Shandong Province, China. lhj82920608@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 16, 2023; 11(32): 7911-7919 Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7911
Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports
Lu Zhang, Ai-Xin Gao, Yu-Lu He, Ming-Jin Xu, Hai-Jun Lu
Lu Zhang, Ming-Jin Xu, Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Ai-Xin Gao, Department of Radiology, The Affiliated hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Yu-Lu He, Department of Pathology, Peking University People's Hospital, Qingdao 266003, Shandong Province, China
Hai-Jun Lu, Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Author contributions: Zhang L contributed to manuscript writing and editing; Gao AX and He YL contributed to data collection; Xu MJ contributed to data analysis; Lu HJ contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Jun Lu, PhD, Professor, Radiation Oncology, The Affiliated Hospital of Qingdao University, Haier Road, Qingdao 266000, Shandong Province, China. lhj82920608@163.com
Received: September 24, 2023 Peer-review started: September 24, 2023 First decision: October 9, 2023 Revised: October 23, 2023 Accepted: November 2, 2023 Article in press: November 2, 2023 Published online: November 16, 2023 Processing time: 52 Days and 15.6 Hours
Abstract
BACKGROUND
SMARCB1/INI-1 deficient sinonasal carcinoma (SDSC) is a rare subset of sinonasal undifferentiated carcinoma with a poor prognosis. Here, we present two case reports of SDSC patients. We also review the literature on this tumor. This is the first published report of SDSC treatment with immunotherapy.
CASE SUMMARY
Here we present two patient cases of SDSC in which initial consultation and diagnosis were complicated but SDSC was ultimately diagnosed. One patient received a traditional treatment of surgery and adjuvant chemoradiotherapy, while the other patient received additional immunotherapy; the prognoses of these two patients differed. We review previous diagnostic literature reports and SDSC treatments and provide a unique perspective on this rare type of tumor.
CONCLUSION
SDSC is a rare, diagnostically challenging carcinoma with a consistently poor prognosis, early distant metastases, and frequent recurrence. Timely diagnosis and intervention are critical for treatment, for which the standard of care is surgery followed by adjuvant chemoradiotherapy, though immunotherapy may be an effective new treatment for SDSC.
Core Tip: SMARCB1/INI-1 deficient sinonasal carcinoma (SDSC) is a rare carcinoma with a poor prognosis and no standard treatment guidelines. Currently, the most effective treatment option is surgery followed by adjuvant chemoradiotherapy. Here, we present two SDSC patients with complicated consultation experiences. The patients differed in treatments and prognoses, and there was no indications of local recurrence or distant metastases in patient with immunotherapy. We also review the literature on SDSC treatment. This first report on immunotherapy in SDSC provides a unique perspective on treatments for this rare tumor.
